Previous 10 | Next 10 |
2024-02-05 07:56:15 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Pharma inks royalty deal fo...
- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application - Marketing Authorization Application accepted by the European Medicines Agency (EMA) with additional global r...
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported over the 30 month acoramidis treatment period - Acoramidis was w...
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics PR Newswire SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partner...
2024-01-18 07:50:08 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Phase 3 data for ATTR-CM dr...
- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue Owl that refinances existing senior secured credit, extending maturity fro...
2024-01-11 17:19:01 ET Summary BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $89...
2024-01-11 11:08:51 ET More on BridgeBio Pharma BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio submits FDA market application for ATTR-CM drug BridgeBio draws Buy rating at Cantor citing 100% up...
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001) - Acoramidis demonstrated ...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is the focus of IBN's latest stock spotlight. The company's shares have moved 4.3% on the day to $25.49. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 ...
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
2024-04-09 22:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demonstrate that targeting near-complete transthyretin (TTR) stabilization wit...
2024-03-20 22:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...